Eydenzelt

Eydenzelt is an intravitreal injection containing aflibercept, used to treat eye conditions like wet age-related macular degeneration. This medication helps slow vision loss by blocking specific growth factors.

Eydenzelt is primarily used for intravitreal administration to manage conditions like wet age-related macular degeneration. It works by inhibiting vascular endothelial growth factor (VEGF), which can help reduce abnormal blood vessel growth in the retina. This medication is often considered when other treatments are not effective or suitable.

Common effects of Eydenzelt may include eye discomfort, redness, or increased floaters. Some patients might experience vision changes or eye inflammation. These effects are typically mild and temporary, but persistent issues should be discussed with a healthcare provider.

Eydenzelt should be handled with care, ensuring proper sterile techniques during administration. Patients should avoid rubbing their eyes after the injection. It is crucial to follow the healthcare provider's instructions for post-injection care to minimize the risk of infection or other complications.

Eydenzelt may interact with other medications, particularly those that affect the immune system or blood clotting. Patients should inform their healthcare provider about all current medications, including over-the-counter drugs and supplements, to avoid potential interactions.